Back to the directory

Mindstate Design Labs

Clinical-stage AI neuroengineering platform

Founded
2021
Status
Active
Stage
Early
Team size
7
Location
San Francisco, CA, USA
Category
Biotech & Drug Discovery
Sector
Drug Discovery and Delivery

About Mindstate Design Labs

We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination emotions in a bottle such as empathy, awe, clarity, or beauty.

AIBiotechMachine LearningMental Health TechTherapeutics

Clinical trials

1 registered trial with this company as lead sponsor, 2024.

Phases
Phase 1 (1)
Status
Completed (1)
Conditions
Mental Health Disorders

NCT06702332

Source: ClinicalTrials.gov.

Securities filings

1 Form D filing on record, 2024.

Filed as Mindstate Design Labs, Inc.

CIK 0002046478

Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.

Company data compiled and maintained by Healthcare Discovery.